Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Abstract Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growt...
Main Authors: | Shang-Gin Wu, Jin-Yuan Shih |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Molecular Cancer |
Online Access: | http://link.springer.com/article/10.1186/s12943-018-0777-1 |
Similar Items
-
Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01) -
An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01) -
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells
by: Donglei Liu, et al.
Published: (2014-03-01) -
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
by: Qiming Wang, et al.
Published: (2019-06-01) -
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)